Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 – 70
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Prevention
Participants needed
404 (estimated)
Sponsor
First Affiliated Hospital of Zhejiang University · Other
Who this trial is looking for
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
This study employs a prospective, randomized, double-blind, placebo-controlled design. It aims to compare the efficacy of etamsylate versus placebo in preventing bleeding complications in patients with thrombocytopenia following hematopoietic stem cell transplantation.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
1. Age between 18 and 70 years (inclusive), regardless of gender;
2. Patients diagnosed with a hematological disease requiring hematopoietic stem cell transplantation;
3. Expected platelet count ≤ 10 x 10⁹/L persisting for 5 days or more;
4. Normal coagulation function;
5. Adequ…
Inclusion Criteria:
1. Age between 18 and 70 years (inclusive), regardless of gender;
2. Patients diagnosed with a hematological disease requiring hematopoietic stem cell transplantation;
3. Expected platelet count ≤ 10 x 10⁹/L persisting for 5 days or more;
4. Normal coagulation function;
5. Adequate organ function: Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 3 times the Upper Limit of Normal (ULN), Total Bilirubin ≤ 2 x ULN; Serum Creatinine ≤ 2 x ULN; Creatinine Clearance ≥ 50 mL/min (calculated using the Cockcroft-Gault formula); Left Ventricular Ejection Fraction (LVEF) ≥ 50% as measured by Echocardiography (ECHO);
6. Voluntary provision of signed informed consent, with the ability to understand and comply with all study requirements.
Exclusion Criteria:
1. Diagnosis of acute promyelocytic leukemia confirmed according to WHO diagnostic criteria;
2. Pregnant or breastfeeding women, and women of childbearing potential unwilling to use effective contraception;
3. Presence of active bleeding or infection;
4. History of diagnosed primary immune thrombocytopenia or hemolytic uremic syndrome;
5. Patients with known hereditary or acquired hemorrhagic disorders;
6. Patients receiving anticoagulant or antiplatelet therapy;
7. Patients with severe cardiac insufficiency (left ventricular ejection fraction \[EF\] \< 60%); or severe arrhythmias: history of clinically significant QTc prolongation (male \> 450 ms; female \> 470 ms), ventricular tachycardia, atrial fibrillation, second-degree heart block; myocardial infarction within 1 year prior to enrollment; or symptomatic coronary artery disease requiring medication; patients with severe liver impairment (liver function indices \[ALT, TBIL\] \> 3 times the upper limit of normal \[ULN\]);
8. Patients with severe pulmonary insufficiency (obstructive and/or restrictive ventilatory defects);
9. Patients with severe renal insufficiency (renal function index \[Cr\] \> 2 times ULN); or 24-hour urinary creatinine clearance rate (Ccr) \< 50 ml/min;
10. Patients with mental disorders or other conditions preventing provision of informed consent and compliance with study treatment and procedural requirements;
11. Other reasons deemed by the investigator to make the patient ineligible for inclusion.
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.